Biomaterials startup Spiderwort designed the product, which uses a plant-based cellulose scaffold to promote spinal cord tissue regeneration after traumatic injuries.
The designation will “increase the speed at which we will initiate our clinical trials,” CEO and co-founder Charles Cuerrier said in a Nov. 12 announcement.
Spiderwort is preparing for a Series A financing round in 2021 as it moves closer to clinical trials.
More articles on biologics:
The most controversial trends in spine from 10 surgeons
Dr. Ali Baaj to build UArizona-Banner spine program from scratch in new role
Investment firm bets big on spine device company that rejected Stryker takeover
